178,537 Labcorp Holdings Inc. $LH Shares Sold by Cooke & Bieler LP

22 Oct 2026, 08:07 by Mitch Edgeman · The Markets Daily

Cooke & Bieler LP decreased its position in Labcorp Holdings Inc. (NYSE:LH – Free Report) by 26.7% in the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 490,641 shares of the medical research company’s stock after selling 178,537 shares during the period. Labcorp accounts for about 2.3% of Cooke & Bieler LP’s investment portfolio, making the stock its 9th biggest position. Cooke & Bieler LP’s holdings in Labcorp were worth $151,171,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. Diamond Hill Capital Management LLC Investment Advisor purchased a new position in Labcorp during the second quarter valued at approximately $168,222,000. Bank of New York Mellon Corp purchased a new stake in Labcorp during the second quarter worth $142,125,000. Madison Asset Management LLC bought a new stake in Labcorp during the 2nd quarter valued at $133,460,000. Bessemer Group Inc. boosted its position in Labcorp by 47.3% during the 1st quarter. Bessemer Group Inc. now owns 579,036 shares of the medical research company’s stock valued at $154,493,000 after acquiring an additional 185,847 shares in the last quarter. Finally, Royal Bank of Canada boosted its position in Labcorp by 19.4% during the 1st quarter. Royal Bank of Canada now owns 820,442 shares of the medical research company’s stock valued at $218,901,000 after acquiring an additional 133,549 shares in the last quarter. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Insider Buying and Selling at Labcorp

In other Labcorp news, EVP Amy Summy sold 924 shares of the firm’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $306.74, for a total value of $283,427.76. Following the completion of the sale, the executive vice president owned 6,956 shares of the company’s stock, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Adam Schechter sold 4,669 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the sale, the chief executive officer owned 102,565 shares in the company, valued at $32,858,749.05. The trade was a 4.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 8,593 shares of company stock worth $2,733,295. 0.84% of the stock is owned by insiders.

Labcorp Stock Performance

Shares of LH opened at $323.39 on Thursday. Labcorp Holdings Inc. has a 12 month low of $244.52 and a 12 month high of $341.80. The stock has a fifty day moving average price of $320.56 and a 200-day moving average price of $290.33. The company has a current ratio of 1.80, a quick ratio of 1.53 and a debt-to-equity ratio of 0.69. The firm has a market cap of $26.23 billion, a PE ratio of 18.48, a P/E/G ratio of 1.84 and a beta of 0.87.

Labcorp (NYSE:LH – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, topping analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a return on equity of 16.74% and a net margin of 6.99%. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. During the same quarter last year, the firm earned $4.35 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Equities research analysts predict that Labcorp Holdings Inc. will post 18.32 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 dividend on an annualized basis and a yield of 0.9%. Labcorp’s dividend payout ratio (DPR) is 23.82%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Piper Sandler boosted their price target on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Robert W. Baird set a $352.00 price objective on Labcorp in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $306.00 price objective on shares of Labcorp in a research report on Friday, July 31st. JPMorgan Chase & Co. lifted their target price on Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Finally, UBS Group lifted their target price on Labcorp from $361.00 to $380.00 and gave the company a “buy” rating in a research note on Friday, September 11th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $337.73.

Read Our Latest Research Report on LH

Labcorp Profile

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.